The new drug policy is a hotchpotch of measures that do not address the many problems typical to the Indian pharmaceutical industry. Its prescriptions - whether with regard to price control, MAPE or FDI regulations - do not take into cognisance the differentiated nature of the sector in India and may well affect the industry negatively in the long run.
To continue reading, become a subscriber.
Explore our attractive subscription offers.
Click here
